Catheter-Related Fungemia Due to Fluconazole-Resistant
            <i>Candida nivariensis</i>

Fujita, Shin-ichi; Senda, Yasuhiro; Okusi, Tikako; Ota, Yumi; Takada, Hiroya; Yamada, Kazunori; Kawano, Mitsuhiro

doi:10.1128/jcm.00727-07

Cited by 49 publications

(47 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Candida bracarensis and Candida nivariensis are two recently described species that are phenotypically identified as Candida glabrata species (1,3,4). However, little is known about the prevalence, antifungal susceptibility patterns, and clinical significances of these two newly discovered species of the C. glabrata clade.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Candida bracarensis Detected among Isolates of Candida glabrata by Peptide Nucleic Acid Fluorescence In Situ Hybridization: Susceptibility Data and Documentation of Presumed Infection

Bishop¹,

Chase²,

Magill

et al. 2008

J Clin Microbiol

View full text Add to dashboard Cite

Molecular taxonomic studies have revealed newCandida species among phenotypically delineated species, the best example being Candida dubliniensis. This study was designed to determine the occurrence of two new molecularly defined species, Candida bracarensis and Candida nivariensis, which are closely related to and identified as Candida glabrata by phenotypic assays. A total of 137 recent clinical isolates of C. glabrata identified by phenotypic characteristics was tested with C. bracarensis and C. nivariensis species-specific peptide nucleic acid fluorescence in situ hybridization probes. Three of 137 (2.2%) isolates were positive with the C. bracarensis probe, whereas the control strain, but none of the clinical isolates, was positive with the C. nivariensis probe. D1/D2 sequencing confirmed the identification of the three isolates as representing C. bracarensis. Clinically, one C. bracarensis isolate was recovered from a presumed infection, a polymicrobial pelvic abscess in a patient with perforated diverticulitis. The other two isolates were recovered from two adult oncology patients who were only colonized. C. bracarensis was white on CHROMagar Candida, had variable API-20C patterns that overlapped with C. nivariensis and some C. glabrata isolates, and had variable results with a rapid trehalose assay. Interestingly, an isolate from one of the colonized oncology patients was resistant to fluconazole, itraconazole, voriconazole, and posaconazole in vitro. In summary, C. bracarensis was detected among clinical isolates of C. glabrata, while C. nivariensis was not. One C. bracarensis isolate causing a presumed deep infection was recovered, and another isolate was azole resistant. Whether clinical laboratories should identify C. bracarensis will require more data.

show abstract

mentioning

confidence: 99%

“…In addition, molecular assays, particularly rRNA gene sequencing, have identified new Candida species that share significant phenotypic characteristics with frequently encountered Candida spp. (1,3,4,7,14).…”

mentioning

confidence: 99%

Candida bracarensis Detected among Isolates of Candida glabrata by Peptide Nucleic Acid Fluorescence In Situ Hybridization: Susceptibility Data and Documentation of Presumed Infection

Bishop¹,

Chase²,

Magill

et al. 2008

J Clin Microbiol

View full text Add to dashboard Cite

show abstract

“…The first three C. nivariensis isolates were reported from the Canary Islands in 2005 from a pulmonary abscess, blood, and urine (1). Since then, single isolates have been reported from a catheter-associated bloodstream infection in Japan and as a cause of oropharyngeal candidiasis in an AIDS patient in Indonesia (6,12). An additional 16 isolates were reported from the United Kingdom, and 9 of these were from sterile body sites, including blood, ascitic fluid, and peritoneal fluid (4).…”

mentioning

confidence: 99%

“…Recent reports have added the Candida glabrata phenotypic mimics Candida nivariensis and Candida bracarensis to this list (2,5). Following a report on 16 isolates from the United Kingdom which indicated that C. nivariensis was an emerging pathogen with multidrug resistance (4,6), we sought to use our unique global collection of Candida isolates to determine what percentage of C. glabrata isolates were C. nivariensis and C. bracarensis and whether these isolates indeed had high rates of resistance to antifungal drugs.…”

mentioning

confidence: 99%

Identification of Candida nivariensis and Candida bracarensis in a Large Global Collection of Candida glabrata Isolates: Comparison to the Literature

Lockhart

Messer

Gherna³

et al. 2009

J Clin Microbiol

View full text Add to dashboard Cite

show abstract

“…3,[5][6][7][8][9][10][11][12] Although C. albicans antifungal susceptibility remains the rule, and reports on resistant isolates are very scarce, other species such as C. krusei, C. glabrata, C. bracarensis, C. nivariensis, C. parapsilosis, and C. guilliermondii are either innately resistant or show decreased susceptibility patterns to azoles, amphotericin B, or echinocandins. [13][14][15][16][17][18][19][20][21] Thus, the therapeutic impact of this shift might be critical and should be considered in patient management. Consistent with this trend, the recent revision of the consensus guidelines actually recommends an adjustment of the treatment according to the isolated Candida species.…”

mentioning

confidence: 99%

Molecular Identification of Closely Related Candida Species Using Two Ribosomal Intergenic Spacer Fingerprinting Methods

Cornet

Sendid

Fradin

et al. 2011

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

Recent changes in the epidemiology of candidiasis highlighted an increase in non-Candida albicans species emphasizing the need for reliable identification methods. Molecular diagnostics in fungal infections may improve species characterization, particularly in cases of the closely related species in the Candida complexes. We developed two PCR/restriction fragment length polymorphism assays, targeting either a part of the intergenic spacer 2 or the entire intergenic spacer (IGS) of ribosomal DNA using a panel of 270 isolates. A part of the intergenic spacer was used for discrimination between C. albicans and C. dubliniensis and between species of the C. glabrata complex (C. glabrata/C. bracarensis/C. nivariensis). The whole IGS was applied to C. parapsilosis, C. metapsilosis, and C. orthopsilosis, and to separate C. famata (Debaryomyces hansenii) from C. guilliermondii (Pichia guilliermondii) and from the other species within this complex (ie, C. carpophila, C. fermentati and C. xestobii). Sharing similar biochemical patterns, Pichia norvegensis and C. inconspicua exhibited specific IGS profiles. Our study confirmed that isolates of C. guilliermondii were frequently misidentified as C. famata. As much as 67% of the clinical isolates phenotypically determined as C. famata were recognized mostly as true P. guilliermondii. Conversely, 44% of the isolates initially identified as C. guilliermondii were corrected by the IGS fingerprints as C. parapsilosis, C. fermentati, or C. zeylanoides. Current changes in the epidemiology of invasive mycoses highlighted a shift in the Candida species involved with a reduced proportion of C. albicans and an increase in non-C. albicans species. [1][2][3][4] In the most recent series, including the large cohort of 2019 patients with candidemia enrolled from 2004 through 2008, C. albicans accounts for less than one half of the isolates.3,5-12 Although C. albicans antifungal susceptibility remains the rule, and reports on resistant isolates are very scarce, other species such as C. krusei, C. glabrata, C. bracarensis, C. nivariensis, C. parapsilosis, and C. guilliermondii are either innately resistant or show decreased susceptibility patterns to azoles, amphotericin B, or echinocandins.13-21 Thus, the therapeutic impact of this shift might be critical and should be considered in patient management. Consistent with this trend, the recent revision of the consensus guidelines actually recommends an adjustment of the treatment according to the isolated Candida species. 22 In yeasts, there is no transfer of resistance between cells and acquisition of resistance, which is mainly observed in restricted clinical settings such as allogeneic blood marrow transplant or AIDS patients under sustained prolonged azole treatment. 5,14,23 Therefore, species identification remains basically predictive of drug susceptibility. Current methods for yeast identification in clinical practice are based on phenotypic features and carbohydrate assimilation tests that require 2 to 5 days or even longer in the case ...

show abstract

Catheter-Related Fungemia Due to Fluconazole-Resistant Candida nivariensis

Cited by 49 publications

References 6 publications

Candida bracarensis Detected among Isolates of Candida glabrata by Peptide Nucleic Acid Fluorescence In Situ Hybridization: Susceptibility Data and Documentation of Presumed Infection

Candida bracarensis Detected among Isolates of Candida glabrata by Peptide Nucleic Acid Fluorescence In Situ Hybridization: Susceptibility Data and Documentation of Presumed Infection

Identification of Candida nivariensis and Candida bracarensis in a Large Global Collection of Candida glabrata Isolates: Comparison to the Literature

Molecular Identification of Closely Related Candida Species Using Two Ribosomal Intergenic Spacer Fingerprinting Methods

Contact Info

Product

Resources

About